Stay updated on Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial page.

Latest updates to the Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial page
- Check5 days agoChange DetectedRevision metadata updated from v3.3.3 to v3.3.4; no substantive study content (eligibility criteria, endpoints, locations, or results) appears to be affected. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check27 days agoChange DetectedUpdated the study's Locations section to add new site locations across the United States and internationally, while removing several previously listed sites. This changes where participants can enroll and access the trial.SummaryDifference2%

- Check56 days agoChange DetectedAdded revision: v3.3.2 to the site footer. Removed revision: v3.2.0.SummaryDifference0.0%

- Check63 days agoChange DetectedAdded a Completed status dated 2025-11-12 and other related date updates; the 'Active, not recruiting' label was removed. The funding-lapse notice previously displayed has been deleted.SummaryDifference0.4%

- Check70 days agoChange DetectedThe 'Last Update Posted' label has been changed to 'Last Update Posted (Estimated)' to indicate the timestamp is an estimate. The previous plain label 'Last Update Posted' has been removed.SummaryDifference0.0%

- Check77 days agoChange DetectedStudy Details page now shows status 'Active, not recruiting' and a 'Last Update Posted' date; outdated 'Recruiting' text and contact details (e.g., Study Coordinator, phone) were removed.SummaryDifference0.3%

Stay in the know with updates to Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial page.